Liisa Bayko
Stock Analyst at Evercore ISI Group
(3.63)
# 810
Out of 5,134 analysts
80
Total ratings
56.06%
Success rate
26.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Liisa Bayko
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Maintains: Outperform | $39 → $37 | $20.18 | +83.35% | 9 | Feb 17, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintains: Outperform | $62 → $74 | $53.17 | +39.18% | 3 | Feb 13, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $475 → $530 | $477.32 | +11.04% | 20 | Jan 23, 2026 | |
| ENTA Enanta Pharmaceuticals | Maintains: Outperform | $20 → $12 | $13.89 | -13.61% | 5 | Sep 15, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $280 → $515 | $332.61 | +54.85% | 2 | Sep 11, 2025 | |
| SVRA Savara | Maintains: In-Line | $3 → $2 | $5.73 | -65.10% | 5 | May 28, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $33 → $45 | $28.75 | +56.52% | 5 | Feb 12, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Outperform | $10 → $12 | $6.95 | +72.66% | 5 | Jan 13, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $7 → $5 | $1.74 | +187.36% | 5 | Dec 16, 2024 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $30 → $35 | $45.38 | -22.87% | 4 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $405 → $360 | $487.32 | -26.13% | 9 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $7 → $2 | $1.06 | +88.68% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $25 | $4.50 | +455.56% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $5.25 | +566.67% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $24 | $42.85 | -43.99% | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $30 | $18.81 | +59.49% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $10 | $4.17 | +139.81% | 1 | Feb 5, 2020 |
Ultragenyx Pharmaceutical
Feb 17, 2026
Maintains: Outperform
Price Target: $39 → $37
Current: $20.18
Upside: +83.35%
CRISPR Therapeutics AG
Feb 13, 2026
Maintains: Outperform
Price Target: $62 → $74
Current: $53.17
Upside: +39.18%
Vertex Pharmaceuticals
Jan 23, 2026
Maintains: Outperform
Price Target: $475 → $530
Current: $477.32
Upside: +11.04%
Enanta Pharmaceuticals
Sep 15, 2025
Maintains: Outperform
Price Target: $20 → $12
Current: $13.89
Upside: -13.61%
Alnylam Pharmaceuticals
Sep 11, 2025
Maintains: Outperform
Price Target: $280 → $515
Current: $332.61
Upside: +54.85%
Savara
May 28, 2025
Maintains: In-Line
Price Target: $3 → $2
Current: $5.73
Upside: -65.10%
Travere Therapeutics
Feb 12, 2025
Maintains: Outperform
Price Target: $33 → $45
Current: $28.75
Upside: +56.52%
BioCryst Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $10 → $12
Current: $6.95
Upside: +72.66%
Editas Medicine
Dec 16, 2024
Maintains: Outperform
Price Target: $7 → $5
Current: $1.74
Upside: +187.36%
Kiniksa Pharmaceuticals International,
Oct 30, 2024
Maintains: Outperform
Price Target: $30 → $35
Current: $45.38
Upside: -22.87%
Aug 8, 2024
Maintains: Outperform
Price Target: $405 → $360
Current: $487.32
Upside: -26.13%
May 16, 2024
Maintains: In-Line
Price Target: $7 → $2
Current: $1.06
Upside: +88.68%
Jan 18, 2023
Maintains: Outperform
Price Target: $14 → $25
Current: $4.50
Upside: +455.56%
Nov 23, 2021
Initiates: Outperform
Price Target: $35
Current: $5.25
Upside: +566.67%
Jun 8, 2021
Initiates: Outperform
Price Target: $24
Current: $42.85
Upside: -43.99%
Nov 24, 2020
Reinstates: Outperform
Price Target: $30
Current: $18.81
Upside: +59.49%
Feb 5, 2020
Upgrades: Market Outperform
Price Target: $10
Current: $4.17
Upside: +139.81%